Chr. Hansen realizes solid organic growth of 10% in the first three months of the financial year 2018/19, delivering in line with our 'Nature’s no. 1 – Sustainably' growth ambitions.
Chr. Hansen reports solid organic revenue growth of 10% in the first three months corresponding to 6% reported growth due to adverse currency impacts: Food Cultures & Enzymes 10%, Health & Nutrition 17% and Natural Colors 6%. EBIT before special items increased by 9% to EUR 71 million, corresponding to an EBIT margin before special items of 26.3% which was up 0.9%-point compared to last year. The overall outlook for 2018/19 remains unchanged.
CEO Mauricio Graber says: “We have had a solid start to the year, with Food Cultures & Enzymes delivering strong organic growth with contributions from volume and EUR pricing, in line with our expectations. Organic growth in Health and Nutrition was also strong, driven by global demand for probiotics for infant formula in Human Health. Animal Health was impacted by timing of orders, but the underlying interest in microbial solutions for animal farming remains strong, and we continue to improve our route-to-market. Plant Health had another excellent quarter in Latin America, although absolute numbers are still modest. We were also pleased to see the momentum in Natural Colors continue in Q1, driven by demand for coloring foodstuff, where we also launched new products for the FRUITMAX® range during Q1.
"Our EBIT margin before special items in Q1 increased by 0.9%-point and was driven by improved margins in Health & Nutrition and Natural Colors. The EBIT margin in Food Cultures & Enzymes was positively impacted by a strong development in gross margin, and ended on par with last year, as we continued to invest in our growth and innovation priorities. We continue to expect a positive contribution from further scalability benefits, as we ramp up utilization of the new capacity in our facility in Copenhagen.
"We are encouraged by the solid start to the year, and we maintain our overall guidance for the full year. Our pipeline of products to be launched this year, from all three business areas, looks very promising and will support the growth potential of Chr. Hansen.”
OUTLOOK FOR 2018/19
The overall outlook for 2018/19 is unchanged compared to the announcement of October 15, 2018
|January 17, 2019||October 15, 2018|
|Organic revenue growth||9-11%||9-11%|
|EBIT margin before special items||around 29.5%||around 29.5%|
|Free cash flow before acquisitions, |
divestments and special items
|around last year||around last year|
The guidance for EBIT margin before special items and for free cash flow before acquisitions, divestments and special items assumes constant currencies from the time of this announcement and for the remainder of the financial year.
|EUR million||Q1 |
|EBIT before special items||70.8||64.7||9%|
|Profit for the period||51.1||46.5||10%|
|Free cash flow before acquisitions and special items||(32.5)||(18.9)||(72)%|
|Organic growth, %||10%||10%|
|Gross margin, %||54.9%||52.5%|
|EBIT margin before special items, %||26.3%||25.4%|
|ROIC excl. goodwill, %||31.4%||30.9%|
科汉森是为食品、营养、制药和农业行业开发天然解决方案的一家全球领先的生物科学公司。我们为各种食品、糖果、饮料、膳食补充剂、动物饲料和植物保护开发和生产发酵剂、酶、益生菌和天然色素。我们的产品创新基于大约 40,000 株微生物菌株——我们喜欢称之为“有益菌群”。我们的解决方案帮助食品制造商实现以更少的资源生产更多的产品，同时也减少了化学添加剂和其他合成物添加剂的使用，这使得我们的产品与当今世界息息相关。可持续性是科汉森改善食物和健康的愿景不可分割的一部分。2019 年，科汉森被 Corporate Knights 评为全球最可持续发展的公司，这要归功于我们为可持续发展付出的巨大努力以及我们与客户建立的众多合作伙伴关系。145 年来，我们一直在不断地为我们的合作伙伴以及全球终端消费者创造价值。令我们感到自豪的是，每天有超过 10 亿人在消费含有我们天然成分的产品。科汉森成立于 1874 年，并已在哥本哈根证券交易所上市。